Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan
Journal of Dental Sciences · 2023-07 · 18 (3) · 1156-1163
DOI: 10.1016/j.jds.2022.10.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dental Sciences, 2023-07. Verfasst von Masanori Nashi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/purpose: The incidence of medication-related osteonecrosis of the jaw is increasing worldwide, mostly due to the use of antiresorptive agents (ARAs) such as bisphosphonate (BP) and denosumab (Dmab). However, the proportion of BP-related osteonecrosis of the jaw (BRONJ) and Dmab-related osteonecrosis of the jaw (DRONJ) among all ARA-related osteonecrosis of the jaw (ARONJ) cases is not clear; this hinders appropriate treatment, recurrence-prevention planning, and avoidance of unnecessary Dmab withdrawal. Moreover, the causative drug administered at each disease stage remains unknown. Therefore, we conducted a retrospective study of patients with ARONJ who visited oral and maxillofacial surgery departments at hospitals in Hyogo Prefecture, Japan, over 3 years to classify and compare patient characteristics with those having BRONJ and DRONJ. We sought to identify the proportion of DRONJ in ARONJ. Materials and methods: After excluding stage 0 patients, 1021 patients were included (471 high-dose; 560 low-dose). ARA treatment for bone metastases of malignant tumors and multiple myeloma was considered high dose, while that for cancer treatment-induced bone loss and osteoporosis was low dose.
Results
Low doses of BP and Dmab accounted for >50% patients; the results differed from those in other countries. DRONJ accounted for 58% and 35% of high-dose and low-dose cases, respectively. Stage 3 ARONJ cases comprised 92 (19.5%) low-dose BRONJ, 39 (20.1%) high-dose BRONJ, 24 (30%) low-dose DRONJ, and 68 (24.5%) high-dose DRONJ. Eighty-nine patients who received switch therapy were divided into BRONJ or DRONJ, but there was no difference in the ratio of each stage compared to the non-switch therapy.
Conclusion
To the best of our knowledge, this is the first study to clarify the proportion of BRONJ and DRONJ cases, causative drug, and its doses by disease stages. DRONJ accounted for approximately 30% of the ARONJ, approximately 60% of which was due to high doses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
- Department of Dentistry and Oral Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
- Department of Oral and Maxillofacial Surgery, Shinsuma General Hospital, Kobe, Hyogo, Japan.
- Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital, Kakogawa, Hyogo, Japan.
- Department of Dentistry and Oral Surgery, Meiwa General Hospital, Nishinomiya, Hyogo, Japan.
- Department of Oral and Maxillofacial Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan.
Zitieren
APA
Nashi, M., Kishimoto, H., Kobayashi, M., Tachibana, A., Suematsu, M., Fujiwara, S., Ota, Y., Hashitani, S., Shibatsuji, T., Nishida, T., Fujimura, K., Furudoi, S., Ishida, Y., Ishii, S., Fujita, T., Iwai, S., Shigeta, T., Harada, T., Miyai, D., …, & Takenobu, T. (2023). Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan. Journal of Dental Sciences, 18(3), 1156-1163. https://doi.org/10.1016/j.jds.2022.10.030
Vancouver
Nashi M, Kishimoto H, Kobayashi M, Tachibana A, Suematsu M, Fujiwara S, et al. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan. Journal of Dental Sciences. 2023;18(3):1156-1163. doi:10.1016/j.jds.2022.10.030
BibTeX
@article{Nashi2023,
author = {Nashi, Masanori and Kishimoto, Hiromitsu and Kobayashi, Masaki and Tachibana, Akira and Suematsu, Motoo and Fujiwara, Shigeyoshi and Ota, Yoshiyuki and Hashitani, Susumu and Shibatsuji, Takeshi and Nishida, Tetsuya and Fujimura, Kazuma and Furudoi, Shungo and Ishida, Yoshiki and Ishii, Shoichiro and Fujita, Tsuyoshi and Iwai, Soichi and Shigeta, Takashi and Harada, Takeshi and Miyai, Daisuke and Takeda, Daisuke and Akashi, Masaya and Noguchi, Kazuma and Takenobu, Toshihiko},
title = {Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan},
journal = {Journal of Dental Sciences},
year = {2023},
volume = {18},
number = {3},
pages = {1156--1163},
doi = {10.1016/j.jds.2022.10.030}
}
EUVIMED